Addition of topical corticosteroids to Dupilimab does not further improve the outcomes in patients with moderate to severe Atopic Dermatitis, finds a study published in the Journal of the European Academy of Dermatology and Venerology.
Atopic dermatitis (AD) is a chronic inflammatory skin disease that can have a significant impact on patients' quality of life. The severity of AD can vary widely between patients, and it is important to understand how treatment responses may differ between patients with severe versus moderate AD.

The study included 1719 patients aged 12 years or older with moderate-to-severe AD from five randomized, double-blind, placebo-controlled trials. Patients were stratified by baseline Investigator's Global Assessment (IGA) score, with a score of 3 indicating moderate AD and a score of 4 indicating severe AD. Patients received subcutaneous placebo or dupilumab as monotherapy or with concomitant topical corticosteroids (TCS).
The results showed that dupilumab-treated patients with moderate AD had numerically higher absolute proportions of patients achieving IGA 0/1 (clear/almost clear) than those with severe AD. However, for all other endpoints assessed, no meaningful differences or consistent response patterns between moderate and severe subgroups were observed. This suggests that dupilumab with or without TCS demonstrated similar efficacy in patients with moderate or severe AD.
The findings of this study are important because they suggest that treatment responses may differ between patients with severe versus moderate AD. This information can be useful for clinicians when selecting treatment options for their patients. In addition, the study highlights the potential benefits of dupilumab as a treatment option for patients with moderate-to-severe AD, regardless of the severity of their condition.
Overall, this study provides valuable insights into the treatment of AD and underscores the importance of individualized treatment plans for patients with different levels of disease severity. It also highlights the need for further research to better understand the underlying mechanisms of AD and to identify new treatment options for this challenging condition.
Source:
Weidinger, S., Simpson, E. L., Silverberg, J. I., Schmitt, J., Leshem, Y. A., Katoh, N., Chen, Z., Zhang, H., Shumel, B., Bansal, A., Chao, J., Lu, Y., Rossi, A. B., & Abramova, A. (2023). Efficacy of dupilumab in moderate and severe atopic dermatitis. In JEADV Clinical Practice. Wiley. https://doi.org/10.1002/jvc2.100